Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injectable solution for intravenous use. It shortens T1 relaxation time of nearby water protons, enhancing signal intensity on T1‑weighted MRI and is employed to improve visualization of brain, spine, liver, cardiovascular system and MR angiography studies.\n\nGNH India supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve visualization of vascular and tissue structures.\n\nMRI of brain: provides enhanced delineation of lesions and vascular anatomy.\nMRI of spine: improves detection of disc pathology and spinal cord abnormalities.\nMRI of liver: enables better characterization of focal liver lesions.\nMRI of cardiovascular system: enhances visualization of cardiac chambers and great vessels.\nMR angiography: offers high‑resolution angiographic images of arteries and veins.

Multihance may cause a range of adverse reactions following intravenous administration.\n\nCommon Side Effects:\n- Nausea\n- Headache\n- Mild injection‑site discomfort\n- Dizziness\n- Warmth or flushing sensation\n- Metallic taste\n\nSerious or Rare Side Effects:\n- Severe allergic reaction or anaphylaxis\n- Nephrogenic systemic fibrosis in patients with severe renal impairment\n- Acute hypotension or cardiovascular collapse\n- Severe respiratory distress\n- Life‑threatening skin reactions such as Stevens‑Johnson syndrome\n- Cardiac arrest

Prior to using Multihance, clinicians should consider several safety measures.\n\nRenal function assessment: evaluate kidney function and avoid use in patients with severe renal impairment.\nPregnancy: use only if clearly needed; safety data are limited.\nBreastfeeding: discontinue breastfeeding or assess risk‑benefit before administration.\nHistory of contrast reaction: review prior hypersensitivity to gadolinium agents.\nConcomitant nephrotoxic drugs: avoid or monitor closely.\nStore at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other agents, requiring careful management.\n\nMajor Interactions (Avoid):\n- Severe renal impairment combined with linear gadolinium agents (increased NSF risk).\n- High‑dose iodinated contrast within 24 h (additive nephrotoxicity).\n- Iron chelators such as deferoxamine (potential alteration of gadolinium clearance).\n\nModerate Interactions (Monitor Closely):\n- Beta‑blockers (may mask hypotensive symptoms).\n- Diuretics (affect renal excretion of gadolinium).\n- Anticoagulants (increase risk of bleeding at injection site).